CAMRF
Camurus AB (publ)
Set alert
- YTD
- -8.01%
- 1 year
- -10.31%
- Open
- 64.00
- Prev close
- 61.75
- Mkt cap
- 3.67B
- Vol
- 200
- Avg vol
- 31
- EPS
- 1.21
- P/E
- 51.03
More statistics
- Low
- 61.75
- High
- 64.00
- Earnings
- Nov 5, 2026
News
3 months ago prnewswire.com
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for…
3 months ago seekingalpha.com
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
4 months ago reuters.com
Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback
Wall Street has pushed to next year expectations for a U.S. approval for Camurus' drug to treat a rare hormonal condition after the health regulator's second refusal on Wednesday.
5 months ago prnewswire.com
Camurus announces expansion of Lilly collaboration
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the…
5 months ago seekingalpha.com
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
8 months ago seekingalpha.com
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
11 months ago seekingalpha.com
Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript
Camurus AB (publ) (OTCPK:CAMRF) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Fredrik Tiberg - President, CEO, CSO & Director Anders Vadsholt - Chief Financial Officer…
1 year ago prnewswire.com
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in…
2 years ago reuters.com
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish…
2 years ago prnewswire.com
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Friday